On June 3, WuXi AppTec (02359.HK) fell 3.01% in regular trading, trading at 125.9 HKD/share, with trading volume of 711 million HKD.
On the news front, the Life Sciences Tools & Services sector came under broad selling pressure, with WuXi Biologics declining 6.37%, WuXi XDC falling 6.48%, and XtalPi dropping 3.11%, reflecting widespread sector weakness. Morgan Stanley disclosed on May 21 that it reduced its long position in WuXi AppTec H-shares from 7.72% to 4.27%, a significant cut whose aftereffects continue to weigh on sentiment.
Despite aggressive buyback efforts — the company repurchased approximately 1.03 million H-shares on June 2 at a cost of around 131.5 million HKD and cancelled 1.2 million previously repurchased shares on June 1 — the short-term selling pressure from the institutional reduction and sector-wide downturn continues to suppress the stock price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments